Neo Ivy Capital Management Adaptive Biotechnologies Corp Transaction History

Neo Ivy Capital Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$10.12 - $28.9 $7,205 - $20,576	-712 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$25.17 - $36.85 $5,109 - $7,480	203 Added 39.88%	712 $19,000
Q3 2021 Nov 16, 2021	BUY	$30.02 - $39.87 $9,486 - $12,598	316 Added 163.73%	509 $25,000
Q2 2021 Aug 16, 2021	BUY	$32.22 - $44.59 $4,543 - $6,287	141 Added 271.15%	193 $8,000
Q1 2021 Oct 07, 2021	SELL	$37.26 - $67.74 $4,582 - $8,332	-123 Reduced 70.29%	52 $2,000
Q4 2020 Feb 16, 2021	SELL	$45.01 - $65.47 $187,556 - $272,813	-4,167 Reduced 95.97%	175 $10,000
Q3 2020 Nov 17, 2020	BUY	$35.79 - $48.81 $155,400 - $211,933	4,342 New	4,342 $211,000
Q2 2020 Aug 17, 2020	SELL	$24.95 - $48.38 $12,699 - $24,625	-509 Closed	0 $0
Q2 2020 Aug 17, 2020	SELL	$24.95 - $48.38 $40,618 - $78,762	-1,628 Reduced 76.18%	509 $25,000
Q1 2020 May 15, 2020	BUY	$16.96 - $34.16 $36,243 - $72,999	2,137 New	2,137 $59,000

206

142M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $1.12B
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.